Genasense Increases Anti-Tumor Activity of Iressa in Preclinical ...

... PharmaLive: Genasense Increases Anti-Tumor Activity of Iressa in Preclinical Models of Non-Small Cell Lung Cancer REGISTERED USERS TODAY ON PHARMALIVE.COM Genasense Increases Anti-Tumor Activity of Iressa in Preclinical Models of Non-Small Cell Lung Cancer Preliminary Data Show Similar Activity with Tarceva and Gefitinib has been recently approved for clinical treatment of patients with advanced NSCLC.

The results were presented today at the annual meeting of the American Association for Cancer Research (AACR) in Anaheim, CA.

Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK).

Recent studies have suggested that clinical response to gefitinib is highly dependent upon the presence of specific mutations in the EGFR gene, which are found in only a small subset of patients with NSCLC.

The present study was undertaken to evaluate whether Genasense could enhance the anticancer response to gefitinib, and also to evaluate whether Genasense could overcome the limitations to gefitinib activity that may be dependent upon EGFR mutations.

Using experimental xenograft models of human NSCLC cells (including A546...

Genasense(R) Increases Anti-Tumor Activity of Iressa(R) in ...

... Genasense(R) Increases Anti-Tumor Activity of Iressa(R) in Preclinical Models of Non-Small Cell Lung Cancer Genasense(R) Increases Anti-Tumor Activity of Iressa(R) in Preclinical Models of Non-Small Cell Lung Cancer Preliminary Data Show Similar Activity with Tarceva(R) and Gefitinib has been recently approved for clinical treatment of patients with advanced NSCLC.

The results were presented today at the annual meeting of the American Association for Cancer Research (AACR) in Anaheim, CA.

Gefitinib is an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK).

Recent studies have suggested that clinical response to gefitinib is highly dependent upon the presence of specific mutations in the EGFR gene, which are found in only a small subset of patients with NSCLC.

The present study was undertaken to evaluate whether Genasense could enhance the anticancer response to gefitinib, and also to evaluate whether Genasense could overcome the limitations to gefitinib activity that may be dependent upon EGFR mutations.

Using experimental xenograft models of human NSCLC cells (including A546, H460,...

Lilly reports strong first quarter

... Lilly reports strong first quarter MARKETPLACE: Classifieds Taurel outlines blueprint for future drug development Other earnings reports Celadon Group Inc.: The Indianapolis-based truckload carrier reported fiscal third-quarter net income increased to $2.7 million from $1.4 million and diluted earnings per share increased to 27 cents from 17 cents in the same quarter last year.3M Co.: The maker of Post-It notes and films for flat-panel televisions said net income grew to $809 million, or $1.03 per share, for the three months ended March 31 from $722 million, or 90 cents per share, a year ago.

Analysts predicted earnings of $1.01 per share.Texas Instruments: The chip maker earned $411 million, or 24 cents per share...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news